Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
Obesity · 2026
DOI: 10.1002/oby.70125 ↗At a glance
Klinische Studie (Phase III) in Obesity, 2026. Written by Jesús Argente and 7 co-authors. Institution: Department of Pediatrics and Pediatric Endocrinology, University Hospital Niño Jesús, Research Institute La Princesa, Madrid, Spain. Major MEDLINE topics: Bardet-Biedl Syndrome, alpha-MSH, Obesity. Cited 2 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Rhythm Pharmaceuticals, Inc., Bardet Biedl Syndrome Foundation and Family Association.
Abstract (original language)
Objective
This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS).
Methods
Patients with BBS ≥ 6 years of age ( n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity‐score matched external control cohort ( n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3‐point decrease in BMI z ‐score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z ‐score, and body weight.
Results
A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls ( p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% ( p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings.
Conclusions
This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS. Trial Registration: ClinicalTrials.gov identifier: NCT03746522
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics and Pediatric Endocrinology, University Hospital Niño Jesús, Research Institute La Princesa, Madrid, Spain.
- Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
- IMDEA, Food Institute, Campus of International Excellence Universidad Autónoma de Madrid (CEIUAM) + Spanish National Research Council (CSIC), Madrid, Spain.
- Division of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
- stradoo Gmbh, Munich, Germany.
Funding
- Rhythm Pharmaceuticals, Inc.
- Bardet Biedl Syndrome Foundation and Family Association
Cite
APA
Argente, J., Haqq, A. M., Schorfheide, J. L., Touchot, N., Huber, C., Wiedemann, U., Pomeroy, J., & Phase 3 BBS Trial Investigators (2026). Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity. https://doi.org/10.1002/oby.70125
Vancouver
Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, et al. Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity. 2026. doi:10.1002/oby.70125
BibTeX
@article{Argente2026,
author = {Argente, Jesús and Haqq, Andrea M and Schorfheide, Jan Luca and Touchot, Nicolas and Huber, Caroline and Wiedemann, Urs and Pomeroy, Jeremy and Phase 3 BBS Trial Investigators, Phase 3 BBS Trial Investigators},
title = {Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70125}
}
EUVIMED